Table 1.

Demographics and baseline characteristics of patients with ANCA-associated vasculitis

CharacteristicVTENo VTEP Value
Subjects22140
Age of onset, yr54.2±19.755.1±16.90.99
Female sex14 (64)84 (60)0.93
Length of follow-up, mo57.3±72.272.9±61.60.04a
Diagnosis0.68
 GPA16 (73)89 (64)
 MPA6 (27)50 (36)
ANCA associations0.01a
 PR3-ANCA18 (82)68 (49)
 MPO-ANCA4 (18)67 (48)
 None0 (0)5 (4)
Smoking status0.41
 Never13 (59)94 (67)
 Prior9 (41)41 (29)
 Current05 (4)
Weight, kg96.3±22.981.3±20.80.005a
Height, m1.68±0.141.68±0.110.56
BMI, kg/m233.3±5.728.3±6.1<0.001a
Obesity (BMI ≥30 kg/m2)15 (68)48 (34)0.01a
Baseline creatinine, µmol/ml, mean (SD)3.0±1.93.0±2.90.29
Baseline GFR, ml/min, mean (SD)35.7±29.646.3±38.80.48
Alveolar hemorrhage, n (%)5 (23)11 (8)0.08
Rapidly progressive GN, n (%)12 (55)36 (26)0.01a
Treated hypertension, n (%)13 (59)77 (55)0.89
Statin treatment, n (%)8 (36)47 (34)0.98
C-reactive protein (0–0.5 mg/L), mean (SD)14.0±21.89.4±23.20.14
Proteinuria (grams/d), mean (SD), mean (SD)2.95±0.66 (20)3.69±0.70 (115)<0.001a
Hypoalbuminemia (<3.0 g/dl), n (%)12 (55)24 (17)<0.001a
Proteinuria (>3500 mg), n (%)0/2014/115 (12)0.21
Rituximab induction, n (%)17 (77)83 (59)0.16
Cyclophosphamide induction, n (%)8 (36)66 (47)0.48
History of malignancy, n (%)06 (4)0.61
Use of aspirin/clopidogrel/warfarin0.59
 Aspirin4 (18)18 (13)
 Clopidogrel00
 Warfarin04 (3)
BVAS at diagnosis, median (range)19 (5–26)14 (2–28)0.01a
  • VTE, venous thromboembolism; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; PR3, proteinase-3; MPO, myeloperoxidase; BMI, body mass index; BVAS, Birmingham Vasculitis Activity Score.

  • a Statistically significant (P<0.05).